drugset / Trial / NCT03563157

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

NCT03563157

Phase 1/2 Terminated 2 enrolled ImmunityBio, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.

Timeline

Start
2018-09-28
Primary completion
2019-04-21
Completion
2019-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldoxorubicin Small molecule
Subject Avelumab Monoclonal antibody
Subject Capecitabine Small molecule
Subject Cetuximab Monoclonal antibody
Subject Cyclophosphamide Other / unclassified
Subject ETBX-011 Vaccine
Subject ETBX-021 Vaccine
Subject ETBX-051 Vaccine
Subject ETBX-061 Vaccine
Subject GI-4000 Vaccine
Subject GI-6207 Vaccine
Subject GI-6301 Vaccine
Subject Leucovorin Small molecule
Subject N-803 Protein / enzyme biologic
Subject Oxaliplatin Small molecule
Subject Paclitaxel Small molecule
Subject Regorafenib Small molecule
Subject fluorouracil Small molecule
Subject haNK Cell therapy

Indications